Innova Therapeutics

Executive Summary

Innova Therapeutics is a private, preclinical-stage biotechnology company headquartered in San Diego, developing a novel monoclonal antibody platform targeting the SFRP2 protein, which is overexpressed in multiple solid tumors. Founded in 2012, the company initially focuses on pediatric osteosarcoma, sarcomas, breast cancer, and pancreatic cancer—areas with high unmet medical need. Innova's approach leverages the role of SFRP2 in tumor growth and immune evasion, aiming to provide a differentiated therapy for patients with limited treatment options. As a preclinical entity, the company has not yet disclosed total funding, valuation, or pipeline details, but its research is supported by its proprietary antibody technology. The near-term value proposition hinges on advancing its lead candidate into investigational new drug (IND)-enabling studies and securing partnerships or financing to move toward clinical trials. Success will depend on demonstrating target engagement and efficacy in preclinical models, as well as navigating the competitive landscape of immuno-oncology. Given the early stage, the company carries significant risk but also potential upside if its platform proves viable in difficult-to-treat cancers.

Upcoming Catalysts (preview)

• Q1 2027Completion of IND-enabling studies for lead candidate40% success
• Q3 2026Presentation of preclinical efficacy data in osteosarcoma models60% success
• TBDAnnouncement of strategic partnership or licensing deal30% success